Campbell & CO Investment Adviser LLC Invests $1.40 Million in Gilead Sciences, Inc. $GILD

Campbell & CO Investment Adviser LLC bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 12,602 shares of the biopharmaceutical company’s stock, valued at approximately $1,399,000.

Several other hedge funds have also recently added to or reduced their stakes in the company. GoalVest Advisory LLC lifted its stake in shares of Gilead Sciences by 7,566.7% in the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares during the period. Corundum Trust Company INC bought a new stake in Gilead Sciences in the third quarter worth approximately $26,000. Harbor Asset Planning Inc. bought a new stake in Gilead Sciences in the second quarter worth approximately $27,000. Putney Financial Group LLC lifted its stake in Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 94 shares during the period. Finally, Howard Hughes Medical Institute bought a new position in shares of Gilead Sciences during the 2nd quarter worth approximately $30,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

GILD stock opened at $124.91 on Friday. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. The business has a 50-day simple moving average of $123.36 and a two-hundred day simple moving average of $118.06. The company has a market capitalization of $154.97 billion, a P/E ratio of 19.37, a price-to-earnings-growth ratio of 0.66 and a beta of 0.33. Gilead Sciences, Inc. has a 52-week low of $91.68 and a 52-week high of $128.70.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. The company had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The company’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter last year, the company earned $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th were issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend was Monday, December 15th. Gilead Sciences’s payout ratio is currently 48.99%.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total value of $372,930.00. Following the transaction, the chief financial officer owned 150,503 shares in the company, valued at $18,709,027.93. The trade was a 1.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Kelly A. Kramer sold 2,805 shares of the company’s stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $127.10, for a total value of $356,515.50. Following the completion of the transaction, the director directly owned 1,339 shares of the company’s stock, valued at approximately $170,186.90. This represents a 67.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 136,757 shares of company stock worth $16,951,612. 0.27% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on GILD shares. The Goldman Sachs Group lifted their price objective on shares of Gilead Sciences from $110.00 to $115.00 and gave the company a “neutral” rating in a research note on Thursday, January 8th. UBS Group reaffirmed a “buy” rating on shares of Gilead Sciences in a research note on Thursday. Scotiabank assumed coverage on shares of Gilead Sciences in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 price objective on the stock. Rothschild & Co Redburn raised their target price on Gilead Sciences from $143.00 to $153.00 in a research note on Monday, November 10th. Finally, Daiwa Capital Markets upped their price target on Gilead Sciences from $128.00 to $129.00 and gave the stock an “outperform” rating in a research note on Thursday, November 13th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $133.16.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.